Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Therapeutic
- Disease
- Genome
- Pharmaceuticals
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6889
License Grant
Licensor hereby grants to Licensee an exclusive License under the Patent Rights, with the right to grant sublicenses through multiple tiers, both subject to the terms and conditions of this Agreement, in the Field of Use and the territory to make, have made, import, use, have used, market, offer for sale, sell and have sold Licensed Products and to practice Licensed Processes.
License Property
US 6,838,437 Inactivation Resistant Factor VIII
US 7,459,534 Inactivation Resistant Factor VIII
US 11/455,116 Inactivation Resistant Factor VIII
US 12/252,024 Method of Producing Factor VIII Proteins by Recombinant Methods
US 12/758,457 Method of Producing Factor VIII Proteins by Recombinant Methods
US 13/015,043 Inactivation Resistant Factor VIII
Field of Use
Field of Use means ex vivo introduction of genes into cells or tissue, said cells or tissue intended to be administered in whole or in part to subjects for therapeutic uses, and specifically excludes the use of transgenic animals or their byproducts for production of Factor VIII molecules.
IPSCIO Record ID: 201028
License Grant
The development and commercialization agreement is to develop and commercialize ELOCTATE and ALPROLIX globally. Each party have specific territories.
License Property
ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], are extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor, thereby making the product last longer in a persons blood than traditional factor therapies.
Field of Use
The agreement is for the drug industry, specifically for clotting-factor therapies.
Elocta is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein.
IPSCIO Record ID: 185232
License Grant
The development and commercialization agreement is to develop and commercialize ELOCTATE and ALPROLIX globally. Each party has specific territories.
License Property
ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein] and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], are extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor, thereby making the product last longer in a persons blood than traditional factor therapies.
Field of Use
The agreement is for the drug industry, specifically for clotting-factor therapies.
IPSCIO Record ID: 237378
License Grant
The License is granted for the purpose of developing, making, using, selling and otherwise disposing of Product.
The Licensor of England grants to the Licensee the following License
(i) a non-exclusive sub-license under United States Patent 4,994,371 to manufacture or have made for it Products and to use, sell or otherwise dispose of, anywhere in the world, Products made in the United States; and,
(ii) a non-exclusive license under the other Patents to manufacture or have made for it Products and to use, sell or otherwise dispose of, anywhere in the world, Products made in the countries covered by the aforesaid other Patents.
License Property
The patents are for Factor IX Gene Clone.
Field of Use
The field of use is human recombinant Factor IX protein produced from cell culture. The Field shall exclude any product, therapy, treatment or procedure in which living material is administered or howsoever brought into contact with the recipient of the therapy, treatment or procedure, or any product made for such purpose. The Field shall also exclude gene therapy or transgenics, or the production by gene therapy, or transgenic animals or transgenic plants, of recombinant Factor IX protein.
IPSCIO Record ID: 328345
License Grant
Generally, by this collaboration, Licensor shall optimize its Existing AsOR Targeted Complex by construction and improvement of plasmid vectors to obtain the required level and duration of Factor VIlI expression from the recombinant Factor VIlI constructs provided by Licensee.
Licensor grants an exclusive license, or in the case of licensed Third Party Patent Rights or Know-How, when permissible, an exclusive sublicense, in the Territory under Licensors Patent Rights, including Licensors rights in any jointly-owned Patent Rights, and Licensors Know How, to conduct the Collaborative Program and to make, use, sell, offer for sale, import, and have made, used, sold, and imported Products for use in the Hemophilia A Field and to each Additional Field(s) upon Licensees exercise of its option(s).
For the License Grant to Licensee Outside the Field(s), for sole inventions and knowhow made by Licensor during the term of and under the Research Program, which are Improvements in the coding and/or non-coding elements for optimizing and/or regulation of gene expression, Licensor grants a world-wide, non-exclusive,
including the right to grant sublicenses, to practice, make, use, sell, import and have practiced, made, used, sold and imported such Improvements for use outside the Field(s).
License Property
Licensor has certain technology regarding the delivery of human genes for use in the prevention and treatment of diseases, states and conditions in humans.
Alternate Ligand-Targeted Complex shall mean a molecular complex comprising a recombinant AsOR ligand or a non-plasma derived ligand such as, but not limited to, a synthetic carbohydrate ligand, said ligand having the ability to bind to the AsOR receptor and which is covalently linked to a polycation and noncovalently bound to DNA.
AsOR shall mean asialoorosomucoid.
Gene shall mean any one of the Factor VIII Gene or the Additional Gene(s), if any. Factor VIII Gene shall mean cDNA for full-length human factor VIII or an engineered deletion or substitution constructs, including B-domain deleted constructs, hereinafter modified, of human factor VIII.
Additional Gene shall mean full length or truncated cDNA for a specific human blood coagulation factor, other than factor VIII, which the parties mutually agree to add to the Collaborative Program and the Agreement.
Field of Use
The collaboration agreement is for development gene therapy products for the treatment of hemophilia A, a hereditary blood clotting disorder.
Field shall mean any one of the Hemophilia A Field or the Additional Field(s), if any; or shall mean, collectively, the Hemophilia A Field and the Additional Field(s).
Additional Field shall mean, the treatment of any blood coagulation disorder in humans using Gene Delivery technology for targeting one or more Additional Gene into a mammalian cell of a patient.
IPSCIO Record ID: 127805
License Grant
The English Licensor grants a non-exclusive license to make, use, sell, offer for sale or import Licensed Products under the Licensed Patents, with a right to grant sublicenses.
License Property
The certain patents relate to the Factor IX gene.
The licensed products mean viral vector products, including without limitation adenovirus (AV) and adeno-associated virus (AAV) viral vector products, for in vivo human gene therapy. Specifically excluded are utilization of non-viral vector products, any ex vivo approach based on the administration of living cells, Factor IX protein produced by or from transgenic animals, and any license rights to make, use, offer for sale, sell, or import Factor IX protein.
Field of Use
This agreement is for the human gene therapy industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
